Skip to main content
Livermore
Livermore
ZHEN

UBS Group AG

SEC CIK
0001610520
Latest filing
Aug 13, 2026

ORMP holding history

Oramed Pharmaceuticals Inc. in every 13F filed by UBS Group AG, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

ORMP overviewAll 13F holders of ORMPFull Q2 2026 holdings

Shares (Q2 2026)
67,671
Value
$325.5K
% of portfolio
<0.1%
Quarters held
22
Since Q1 2021
Holdings of ORMP by UBS Group AG, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q2 202667,671$325.5K<0.1%+56,004+480.0%AddedHolders
Q1 202611,667$39.7K<0.1%+9,092+353.1%AddedHolders
Q4 20252,575$7.34K<0.1%+2,218+621.3%AddedHolders
Q3 2025357$943<0.1%−12,422−97.2%ReducedHolders
Q2 202512,779$28.8K<0.1%−22,804−64.1%ReducedHolders
Q1 202535,583$76.1K<0.1%−77,398−68.5%ReducedHolders
Q4 2024112,981$273.4K<0.1%+84,797+300.9%AddedHolders
Q3 202428,184$68.8K<0.1%+18,893+203.3%AddedHolders
Q2 20249,291$23.9K<0.1%+4,642+99.8%AddedHolders
Q1 20244,649$13.6K<0.1%−417−8.2%ReducedHolders
Q4 20235,066$11.7K<0.1%−1,140−18.4%ReducedHolders
Q3 20236,206$16.2K<0.1%+64+1.0%AddedHolders
Q2 20236,142$22.0K<0.1%−92,992−93.8%ReducedHolders
Q1 202399,134$216.1K<0.1%+88,422+825.4%AddedHolders
Q4 202210,712$128.9K<0.1%+2,297+27.3%AddedHolders
Q3 20228,415$54.0K<0.1%+3,864+84.9%AddedHolders
Q2 20224,551$21.0K<0.1%+1,520+50.1%AddedHolders
Q1 20223,031$26.0K<0.1%−10,645−77.8%ReducedHolders
Q4 202113,676$195.0K<0.1%+12,502+1,064.9%AddedHolders
Q3 20211,174$26.0K<0.1%−25,507−95.6%ReducedHolders
Q2 202126,681$357.0K<0.1%+24,898+1,396.4%AddedHolders
Q1 20211,783$18.0K<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.